SlideShare a Scribd company logo
Hemodynamic Disorders
Hemodynamic Disorders
 Edema
 Edema
 Hyperemia and Congestion
 Hyperemia and Congestion
 Hemorrhage
 Hemorrhage
 Hemostasis and Thrombosis
 Hemostasis and Thrombosis
 Embolism
 Embolism
 Infarction
 Infarction
 Shock
 Shock
1

Dr. Krishna Tadepalli, MD, www.mletips.com
Feature

Hemostasis

Thrombosis

What is it?

Blood clot

Blood clot

Where is it?

Site of vascular
injury

In an uninjured
vessel

Why is it?

Trauma
(common)

Atherosclerosis

What happens
later?

Stops blood loss Produce
(deserved effect) complications
(Emboli)

2

Dr. Krishna Tadepalli, MD, www.mletips.com
Hemostasis
Hemostasis
 Events following vascular injury
 Events following vascular injury
 1. transient vasoconstriction ( by neurogenic
 1. transient vasoconstriction ( by neurogenic
mechanisms, Endothelin – vasoconstrictor of
mechanisms, Endothelin – vasoconstrictor of
Endothelial cells), reduce blood loss
Endothelial cells), reduce blood loss
 2. Primary Hemostasis  formation of Primary
 2. Primary Hemostasis  formation of Primary
haemostatic plug (( by platelet adhesion, activation
haemostatic plug by platelet adhesion, activation
& Aggregation),
& Aggregation),
 3. Secondary Hemostasis  Platelets + Fibrin
 3. Secondary Hemostasis  Platelets + Fibrin
(( from coagulation pathways- either intrinsic or
from coagulation pathways- either intrinsic or
extrinsic), forms secondary haemostatic plug
extrinsic), forms secondary haemostatic plug
3

Dr. Krishna Tadepalli, MD, www.mletips.com
Hemostasis
Hemostasis
 Role of Endothelium
 Role of Endothelium
 1. Produce Pro-thrombotic (( Plasminogen
 1. Produce Pro-thrombotic Plasminogen
activator inhibitors – PAI, Tissue factor, vWF)
activator inhibitors – PAI, Tissue factor, vWF)
and Anti-thrombotic factors (( Vasodilators –
and Anti-thrombotic factors Vasodilators –
PGI2, NO; tPA, Heparin like molecules &
PGI2, NO; tPA, Heparin like molecules &
Thombomodulin)
Thombomodulin)
 2. Balance of these factors determine the end result
 2. Balance of these factors determine the end result
(( clot or dissolution of clot)
clot or dissolution of clot)

4

Dr. Krishna Tadepalli, MD, www.mletips.com
PAI

5

Dr. Krishna Tadepalli, MD, www.mletips.com
Coagulation pathway
Coagulation pathway

 Role of Platelets
 Role of Platelets
 Granules  α granules( contain clotting factors &
 Granules  α granules( contain clotting factors &
Growth factors), Dense or δ granules (( ADP, Ca++++,
Growth factors), Dense or δ granules ADP, Ca ,
Neuropeptides, Epinephrine)
Neuropeptides, Epinephrine)
 Response to injury  bind to sub-endothelial
 Response to injury  bind to sub-endothelial
ECM (( vWF + Gp -Ib) Adhesion
ECM vWF + Gp -Ib) Adhesion
 Expose Phospholipid complexes (helps in intrinsic
 Expose Phospholipid complexes (helps in intrinsic
clotting pathway) & release ADP& Ca++++
clotting pathway) & release ADP& Ca
 Aggregate with other platelets (( with fibrin by Gp
 Aggregate with other platelets with fibrin by Gp
IIb-IIIa on platelet surfaces
IIb-IIIa on platelet surfaces
6

Dr. Krishna Tadepalli, MD, www.mletips.com
Hemostasis

7

Dr. Krishna Tadepalli, MD, www.mletips.com
Aspirin in patients at risk for coronary thrombosis8
It irreversibly acetylates and inactivates cyclooxygenase-1  due to
its ability to block TxA2 synthesis EQ
Dr. Krishna Tadepalli, MD, www.mletips.com
9

Dr. Krishna Tadepalli, MD, www.mletips.com
Coagulation pathway
Coagulation pathway

10

Dr. Krishna Tadepalli, MD, www.mletips.com
Coagulation pathway
Coagulation pathway

 Most important step in this pathway
 Most important step in this pathway
(either intrinsic or extrinsic)  formation of
(either intrinsic or extrinsic)  formation of
Thrombin
Thrombin
 Thrombin produces it effects  through
 Thrombin produces it effects  through
PARS( Protease activated receptors – 7 GPCR
PARS( Protease activated receptors – 7 GPCR
family)
family)
 Major effects of Thrombin
 Major effects of Thrombin
 Fibrin formation from Fibrinogen
 Fibrin formation from Fibrinogen
 On Platelets TxA2
 On Platelets TxA2
 On Endothelial cells NO, tPA, PGI2
 On Endothelial cells NO, tPA, PGI2
 act also on Lymphocytes, Neutrophils, Monocytes
 act also on Lymphocytes, Neutrophils, Monocytes

11

Dr. Krishna Tadepalli, MD, www.mletips.com
Coagulation pathway
Coagulation pathway
 Thrombin
 Thrombin

12

Dr. Krishna Tadepalli, MD, www.mletips.com
Anti -- Coagulants
Anti Coagulants
Natural ones
Natural ones

 1. Antithrombins( AT-III)  inactivate Thrombin;
 1. Antithrombins( AT-III)  inactivate Thrombin;
Factors IX to XII; bind to heparin like molecule on
Factors IX to XII; bind to heparin like molecule on
endothelium
endothelium
 2. Proteins – C & S  produced by liver; need Vit. K for
 2. Proteins – C & S  produced by liver; need Vit. K for
activation; inactivate Factors V, VIII
activation; inactivate Factors V, VIII
 Tissue Factor Pathway Inhibitors (TFPI)  inhibit
 Tissue Factor Pathway Inhibitors (TFPI)  inhibit
factors VII, X
factors VII, X
Clinical significance
Clinical significance

Heparin act through AT-III; Monitor PTT (Intrinsic pathway), Antidote is
Heparin act through AT-III; Monitor PTT (Intrinsic pathway), Antidote is
Protamine, can produce HIT (heparin induced thrombocytopenia); can be
Protamine, can produce HIT (heparin induced thrombocytopenia); can be
given in pregnancy (as it can’t cross placenta); need frequent injections
given in pregnancy (as it can’t cross placenta); need frequent injections
Warfarin  act through inhibition of Vit K mediated carboxylation of
Warfarin  act through inhibition of Vit K mediated carboxylation of
clotting factors (II,VII, IX, X); Extrinsic pathway Monitor PT; Antidote is
13
clotting factors (II,VII, IX, X); Extrinsic pathway Monitor PT; Antidote is
Vit.K contraindicated in pregnancy (teratogenic)
Vit.K1 1;;contraindicated in pregnancy (teratogenic)
Dr. Krishna Tadepalli, MD, www.mletips.com
Fibrinolytic pathway
Fibrinolytic pathway

 Most important step in this pathway
 Most important step in this pathway
 formation of Plasmin from Plasminogen
 formation of Plasmin from Plasminogen
 Tissue Plasminogen activator (tPA) is important in this
 Tissue Plasminogen activator (tPA) is important in this
conversion
conversion

 Plasmin  breaks down excess Fibrin  Fibrin split
 Plasmin  breaks down excess Fibrin  Fibrin split
products or Fibrin degradation products (FSP or FDP)
products or Fibrin degradation products (FSP or FDP)

 Most important component of FDP  D-dimer
 Most important component of FDP  D-dimer
Clinical significance
Clinical significance

D-dimer positivity (≥200 ng) patient had clot and it is lysed by
D-dimer positivity (≥200 ng) patient had clot and it is lysed by
Plasmin
Plasmin
Conditions where D-dimer is positive  DIC, DVT, PE
Conditions where D-dimer is positive  DIC, DVT, PE

14

Dr. Krishna Tadepalli, MD, www.mletips.com
Fibrinolytic pathway
Fibrinolytic pathway

15

Dr. Krishna Tadepalli, MD, www.mletips.com

More Related Content

What's hot

08 dic
08 dic08 dic
Coagulation Proteins and Bleeding Disorders
 Coagulation Proteins and Bleeding Disorders Coagulation Proteins and Bleeding Disorders
Coagulation Proteins and Bleeding Disorders
Marcelo Santos
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
Indian dental academy
 
Homeostasis And Clotting Factor And DIC
Homeostasis And Clotting Factor And DICHomeostasis And Clotting Factor And DIC
Homeostasis And Clotting Factor And DIC
Mohammad Abdeljawad
 
Bleeding disorders copy
Bleeding disorders   copyBleeding disorders   copy
Bleeding disorders copy
Indian dental academy
 
Bleeding Disorders: Causes, Types, and Diagnosis
Bleeding Disorders: Causes, Types, and Diagnosis Bleeding Disorders: Causes, Types, and Diagnosis
Bleeding Disorders: Causes, Types, and Diagnosis
Dr Medical
 
Dic
DicDic
Disseminated intra vascular coagulation
Disseminated intra vascular coagulationDisseminated intra vascular coagulation
Disseminated intra vascular coagulation
Priya
 
DIC Presentation
DIC PresentationDIC Presentation
DIC Presentation
Salsabil A.
 
DIC
DICDIC
Thrombosis complete
Thrombosis completeThrombosis complete
Hemorrhagic disorders march 2020
Hemorrhagic disorders  march 2020Hemorrhagic disorders  march 2020
Hemorrhagic disorders march 2020
Micheal Mikael
 
Hemostasis and its disorders
Hemostasis and its disordersHemostasis and its disorders
Hemostasis and its disorders
dina merzeban
 
Bleeding disorders /certified fixed orthodontic courses by Indian dental aca...
Bleeding disorders  /certified fixed orthodontic courses by Indian dental aca...Bleeding disorders  /certified fixed orthodontic courses by Indian dental aca...
Bleeding disorders /certified fixed orthodontic courses by Indian dental aca...
Indian dental academy
 
Bleeding disorders Causes, Types, and Diagnosis
Bleeding disorders Causes, Types, and DiagnosisBleeding disorders Causes, Types, and Diagnosis
Bleeding disorders Causes, Types, and Diagnosis
Dr Medical
 
Approach to bleeding disorders part 1
Approach to bleeding disorders part 1Approach to bleeding disorders part 1
Approach to bleeding disorders part 1
drbcnayak
 
Approach to Disseminated intravascular coagulation
Approach to Disseminated intravascular coagulationApproach to Disseminated intravascular coagulation
Approach to Disseminated intravascular coagulation
Rajeswaran Sorna Moorthy
 
Disseminated intravascular coagulation (dic)
Disseminated intravascular coagulation (dic)Disseminated intravascular coagulation (dic)
Disseminated intravascular coagulation (dic)amanmauryambbs
 
Haemostasis
HaemostasisHaemostasis
Haemostasis
Richin Koshy
 

What's hot (20)

08 dic
08 dic08 dic
08 dic
 
Coagulation Proteins and Bleeding Disorders
 Coagulation Proteins and Bleeding Disorders Coagulation Proteins and Bleeding Disorders
Coagulation Proteins and Bleeding Disorders
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
Homeostasis And Clotting Factor And DIC
Homeostasis And Clotting Factor And DICHomeostasis And Clotting Factor And DIC
Homeostasis And Clotting Factor And DIC
 
Bleeding disorders copy
Bleeding disorders   copyBleeding disorders   copy
Bleeding disorders copy
 
Bleeding Disorders: Causes, Types, and Diagnosis
Bleeding Disorders: Causes, Types, and Diagnosis Bleeding Disorders: Causes, Types, and Diagnosis
Bleeding Disorders: Causes, Types, and Diagnosis
 
Dic
DicDic
Dic
 
Disseminated intra vascular coagulation
Disseminated intra vascular coagulationDisseminated intra vascular coagulation
Disseminated intra vascular coagulation
 
DIC Presentation
DIC PresentationDIC Presentation
DIC Presentation
 
DIC
DICDIC
DIC
 
Hemophilia
HemophiliaHemophilia
Hemophilia
 
Thrombosis complete
Thrombosis completeThrombosis complete
Thrombosis complete
 
Hemorrhagic disorders march 2020
Hemorrhagic disorders  march 2020Hemorrhagic disorders  march 2020
Hemorrhagic disorders march 2020
 
Hemostasis and its disorders
Hemostasis and its disordersHemostasis and its disorders
Hemostasis and its disorders
 
Bleeding disorders /certified fixed orthodontic courses by Indian dental aca...
Bleeding disorders  /certified fixed orthodontic courses by Indian dental aca...Bleeding disorders  /certified fixed orthodontic courses by Indian dental aca...
Bleeding disorders /certified fixed orthodontic courses by Indian dental aca...
 
Bleeding disorders Causes, Types, and Diagnosis
Bleeding disorders Causes, Types, and DiagnosisBleeding disorders Causes, Types, and Diagnosis
Bleeding disorders Causes, Types, and Diagnosis
 
Approach to bleeding disorders part 1
Approach to bleeding disorders part 1Approach to bleeding disorders part 1
Approach to bleeding disorders part 1
 
Approach to Disseminated intravascular coagulation
Approach to Disseminated intravascular coagulationApproach to Disseminated intravascular coagulation
Approach to Disseminated intravascular coagulation
 
Disseminated intravascular coagulation (dic)
Disseminated intravascular coagulation (dic)Disseminated intravascular coagulation (dic)
Disseminated intravascular coagulation (dic)
 
Haemostasis
HaemostasisHaemostasis
Haemostasis
 

Viewers also liked

1. edema; hemodynamic disorders
1. edema; hemodynamic disorders1. edema; hemodynamic disorders
1. edema; hemodynamic disordersKrishna Tadepalli
 
2. heart pathology; congenital disorders
2. heart pathology; congenital disorders2. heart pathology; congenital disorders
2. heart pathology; congenital disordersKrishna Tadepalli
 
5.heart pathology; valvular heart diseases
5.heart pathology; valvular heart diseases5.heart pathology; valvular heart diseases
5.heart pathology; valvular heart diseasesKrishna Tadepalli
 
Heart pathology
Heart pathologyHeart pathology
Heart pathology
Ganapathy Tamilselvan
 
2. hyperemia and congestion; hemodynamic disorders
2. hyperemia and congestion; hemodynamic disorders2. hyperemia and congestion; hemodynamic disorders
2. hyperemia and congestion; hemodynamic disordersKrishna Tadepalli
 
3. heart patghology; ischemic heart diseases
3. heart patghology; ischemic heart diseases3. heart patghology; ischemic heart diseases
3. heart patghology; ischemic heart diseasesKrishna Tadepalli
 
Cardiovascular Pathology (part 1)
Cardiovascular Pathology (part 1)Cardiovascular Pathology (part 1)
Cardiovascular Pathology (part 1)
Louie Ray
 
Heart Disease
Heart DiseaseHeart Disease
Heart Disease
Severus Prime
 

Viewers also liked (8)

1. edema; hemodynamic disorders
1. edema; hemodynamic disorders1. edema; hemodynamic disorders
1. edema; hemodynamic disorders
 
2. heart pathology; congenital disorders
2. heart pathology; congenital disorders2. heart pathology; congenital disorders
2. heart pathology; congenital disorders
 
5.heart pathology; valvular heart diseases
5.heart pathology; valvular heart diseases5.heart pathology; valvular heart diseases
5.heart pathology; valvular heart diseases
 
Heart pathology
Heart pathologyHeart pathology
Heart pathology
 
2. hyperemia and congestion; hemodynamic disorders
2. hyperemia and congestion; hemodynamic disorders2. hyperemia and congestion; hemodynamic disorders
2. hyperemia and congestion; hemodynamic disorders
 
3. heart patghology; ischemic heart diseases
3. heart patghology; ischemic heart diseases3. heart patghology; ischemic heart diseases
3. heart patghology; ischemic heart diseases
 
Cardiovascular Pathology (part 1)
Cardiovascular Pathology (part 1)Cardiovascular Pathology (part 1)
Cardiovascular Pathology (part 1)
 
Heart Disease
Heart DiseaseHeart Disease
Heart Disease
 

Similar to 4. hemostasis; hemodynamic disorders

Thrombophilia.ppt
Thrombophilia.pptThrombophilia.ppt
Thrombophilia.ppt
AbdulKaderSouid
 
Moore Chapter: Thrombolysis
Moore Chapter: ThrombolysisMoore Chapter: Thrombolysis
Moore Chapter: Thrombolysisagucwa
 
khaalid blood
khaalid bloodkhaalid blood
khaalid blood
Khaalid Hassan
 
Anticoagulation in diagnostic and interventional procedure and monitoring a...
Anticoagulation  in diagnostic and interventional procedure and monitoring  a...Anticoagulation  in diagnostic and interventional procedure and monitoring  a...
Anticoagulation in diagnostic and interventional procedure and monitoring a...
Deb Boruah
 
Pt Aptt 1218181287688715 8
Pt Aptt 1218181287688715 8Pt Aptt 1218181287688715 8
Pt Aptt 1218181287688715 8rudy184
 
Immune supp-meds-al-absi-09 is
Immune supp-meds-al-absi-09 isImmune supp-meds-al-absi-09 is
Immune supp-meds-al-absi-09 is
Brijesh Kushwaha
 
PT APTT Technical Information
PT APTT Technical InformationPT APTT Technical Information
PT APTT Technical InformationPriyank Dubey
 
Drugs acting on the blood and blood forming organs
Drugs acting on the blood and blood forming organsDrugs acting on the blood and blood forming organs
Drugs acting on the blood and blood forming organs
UDPS
 
bleedig & clotting disorders
 bleedig & clotting disorders bleedig & clotting disorders
bleedig & clotting disorders
Dr Nikita panpaliya
 
Pharmacology- Drugs Affecting the Blood
Pharmacology- Drugs Affecting the BloodPharmacology- Drugs Affecting the Blood
Pharmacology- Drugs Affecting the Blood
Imhotep Virtual Medical School
 
Normal haemostasis
Normal haemostasisNormal haemostasis
Normal haemostasis
gaurav kumar
 
Normal haemostasis
Normal haemostasisNormal haemostasis
Normal haemostasis
gaurav kumar
 
Autacoids(par ii)
Autacoids(par ii)Autacoids(par ii)
Autacoids(par ii)
jyoti chauhan
 
Haemostasis and thrombosis ppt
Haemostasis and thrombosis pptHaemostasis and thrombosis ppt
Haemostasis and thrombosis ppt
ali7070
 
Woods Anticoag Antianem 09
Woods Anticoag Antianem 09Woods Anticoag Antianem 09
Woods Anticoag Antianem 09pharmdude
 
Anti coagulationin patient with ckd Prof.Basset El Essawy MD ph D
Anti coagulationin patient with ckd Prof.Basset El Essawy  MD ph DAnti coagulationin patient with ckd Prof.Basset El Essawy  MD ph D
Anti coagulationin patient with ckd Prof.Basset El Essawy MD ph D
FarragBahbah
 

Similar to 4. hemostasis; hemodynamic disorders (20)

Thrombophilia.ppt
Thrombophilia.pptThrombophilia.ppt
Thrombophilia.ppt
 
Agents used in coagulation disorders
Agents used in coagulation disorders Agents used in coagulation disorders
Agents used in coagulation disorders
 
CME: Bleeding Disorders - Applied Physiology
CME: Bleeding Disorders - Applied PhysiologyCME: Bleeding Disorders - Applied Physiology
CME: Bleeding Disorders - Applied Physiology
 
Moore Chapter: Thrombolysis
Moore Chapter: ThrombolysisMoore Chapter: Thrombolysis
Moore Chapter: Thrombolysis
 
khaalid blood
khaalid bloodkhaalid blood
khaalid blood
 
Anticoagulation in diagnostic and interventional procedure and monitoring a...
Anticoagulation  in diagnostic and interventional procedure and monitoring  a...Anticoagulation  in diagnostic and interventional procedure and monitoring  a...
Anticoagulation in diagnostic and interventional procedure and monitoring a...
 
Pt Aptt 1218181287688715 8
Pt Aptt 1218181287688715 8Pt Aptt 1218181287688715 8
Pt Aptt 1218181287688715 8
 
Immune supp-meds-al-absi-09 is
Immune supp-meds-al-absi-09 isImmune supp-meds-al-absi-09 is
Immune supp-meds-al-absi-09 is
 
PT APTT Technical Information
PT APTT Technical InformationPT APTT Technical Information
PT APTT Technical Information
 
Koenig aeha2005 short
Koenig aeha2005 shortKoenig aeha2005 short
Koenig aeha2005 short
 
Drugs acting on the blood and blood forming organs
Drugs acting on the blood and blood forming organsDrugs acting on the blood and blood forming organs
Drugs acting on the blood and blood forming organs
 
Enoxaparin
EnoxaparinEnoxaparin
Enoxaparin
 
bleedig & clotting disorders
 bleedig & clotting disorders bleedig & clotting disorders
bleedig & clotting disorders
 
Pharmacology- Drugs Affecting the Blood
Pharmacology- Drugs Affecting the BloodPharmacology- Drugs Affecting the Blood
Pharmacology- Drugs Affecting the Blood
 
Normal haemostasis
Normal haemostasisNormal haemostasis
Normal haemostasis
 
Normal haemostasis
Normal haemostasisNormal haemostasis
Normal haemostasis
 
Autacoids(par ii)
Autacoids(par ii)Autacoids(par ii)
Autacoids(par ii)
 
Haemostasis and thrombosis ppt
Haemostasis and thrombosis pptHaemostasis and thrombosis ppt
Haemostasis and thrombosis ppt
 
Woods Anticoag Antianem 09
Woods Anticoag Antianem 09Woods Anticoag Antianem 09
Woods Anticoag Antianem 09
 
Anti coagulationin patient with ckd Prof.Basset El Essawy MD ph D
Anti coagulationin patient with ckd Prof.Basset El Essawy  MD ph DAnti coagulationin patient with ckd Prof.Basset El Essawy  MD ph D
Anti coagulationin patient with ckd Prof.Basset El Essawy MD ph D
 

More from Krishna Tadepalli

7. tumors; pediatric pathology
7. tumors; pediatric pathology7. tumors; pediatric pathology
7. tumors; pediatric pathologyKrishna Tadepalli
 
4. hydrops fetalis; pedatric pathology
4. hydrops fetalis; pedatric pathology4. hydrops fetalis; pedatric pathology
4. hydrops fetalis; pedatric pathologyKrishna Tadepalli
 
6. sudden infant death syndrome (sids); pediatric pathology
6. sudden infant death syndrome (sids); pediatric pathology6. sudden infant death syndrome (sids); pediatric pathology
6. sudden infant death syndrome (sids); pediatric pathologyKrishna Tadepalli
 
5. metabolic and genetic disorders; pediatric pathology
5. metabolic and genetic disorders; pediatric pathology5. metabolic and genetic disorders; pediatric pathology
5. metabolic and genetic disorders; pediatric pathologyKrishna Tadepalli
 
3. perinatal infections; pediatric pathology
3. perinatal infections; pediatric pathology3. perinatal infections; pediatric pathology
3. perinatal infections; pediatric pathologyKrishna Tadepalli
 
2.disorders of prematurity; pediatric pathology
2.disorders of prematurity; pediatric  pathology2.disorders of prematurity; pediatric  pathology
2.disorders of prematurity; pediatric pathologyKrishna Tadepalli
 
10.1 congenital anomalies; pediatric pathology
10.1 congenital anomalies; pediatric pathology10.1 congenital anomalies; pediatric pathology
10.1 congenital anomalies; pediatric pathologyKrishna Tadepalli
 
10. heart pathology; transplantation
10. heart pathology; transplantation10. heart pathology; transplantation
10. heart pathology; transplantationKrishna Tadepalli
 
8. heart pathoogy; pericardial diseases
8. heart pathoogy; pericardial diseases8. heart pathoogy; pericardial diseases
8. heart pathoogy; pericardial diseasesKrishna Tadepalli
 
9. hear pathology; neoplasms
9. hear pathology; neoplasms9. hear pathology; neoplasms
9. hear pathology; neoplasmsKrishna Tadepalli
 
4. heart pathology; hypertensive heart diseases
4. heart pathology; hypertensive heart diseases4. heart pathology; hypertensive heart diseases
4. heart pathology; hypertensive heart diseasesKrishna Tadepalli
 
7. heart pathology; myocadial diseases
7. heart pathology; myocadial diseases7. heart pathology; myocadial diseases
7. heart pathology; myocadial diseasesKrishna Tadepalli
 
1. heart pathology; heart failure
1. heart pathology; heart failure1. heart pathology; heart failure
1. heart pathology; heart failureKrishna Tadepalli
 

More from Krishna Tadepalli (13)

7. tumors; pediatric pathology
7. tumors; pediatric pathology7. tumors; pediatric pathology
7. tumors; pediatric pathology
 
4. hydrops fetalis; pedatric pathology
4. hydrops fetalis; pedatric pathology4. hydrops fetalis; pedatric pathology
4. hydrops fetalis; pedatric pathology
 
6. sudden infant death syndrome (sids); pediatric pathology
6. sudden infant death syndrome (sids); pediatric pathology6. sudden infant death syndrome (sids); pediatric pathology
6. sudden infant death syndrome (sids); pediatric pathology
 
5. metabolic and genetic disorders; pediatric pathology
5. metabolic and genetic disorders; pediatric pathology5. metabolic and genetic disorders; pediatric pathology
5. metabolic and genetic disorders; pediatric pathology
 
3. perinatal infections; pediatric pathology
3. perinatal infections; pediatric pathology3. perinatal infections; pediatric pathology
3. perinatal infections; pediatric pathology
 
2.disorders of prematurity; pediatric pathology
2.disorders of prematurity; pediatric  pathology2.disorders of prematurity; pediatric  pathology
2.disorders of prematurity; pediatric pathology
 
10.1 congenital anomalies; pediatric pathology
10.1 congenital anomalies; pediatric pathology10.1 congenital anomalies; pediatric pathology
10.1 congenital anomalies; pediatric pathology
 
10. heart pathology; transplantation
10. heart pathology; transplantation10. heart pathology; transplantation
10. heart pathology; transplantation
 
8. heart pathoogy; pericardial diseases
8. heart pathoogy; pericardial diseases8. heart pathoogy; pericardial diseases
8. heart pathoogy; pericardial diseases
 
9. hear pathology; neoplasms
9. hear pathology; neoplasms9. hear pathology; neoplasms
9. hear pathology; neoplasms
 
4. heart pathology; hypertensive heart diseases
4. heart pathology; hypertensive heart diseases4. heart pathology; hypertensive heart diseases
4. heart pathology; hypertensive heart diseases
 
7. heart pathology; myocadial diseases
7. heart pathology; myocadial diseases7. heart pathology; myocadial diseases
7. heart pathology; myocadial diseases
 
1. heart pathology; heart failure
1. heart pathology; heart failure1. heart pathology; heart failure
1. heart pathology; heart failure
 

Recently uploaded

Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
Ana-Maria Mihalceanu
 
GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...
ThomasParaiso2
 
Essentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FMEEssentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FME
Safe Software
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
BookNet Canada
 
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdfSAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
Peter Spielvogel
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
Dorra BARTAGUIZ
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
Neo4j
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
Matthew Sinclair
 
Climate Impact of Software Testing at Nordic Testing Days
Climate Impact of Software Testing at Nordic Testing DaysClimate Impact of Software Testing at Nordic Testing Days
Climate Impact of Software Testing at Nordic Testing Days
Kari Kakkonen
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
Neo4j
 
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdfFIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
FIDO Alliance
 
State of ICS and IoT Cyber Threat Landscape Report 2024 preview
State of ICS and IoT Cyber Threat Landscape Report 2024 previewState of ICS and IoT Cyber Threat Landscape Report 2024 preview
State of ICS and IoT Cyber Threat Landscape Report 2024 preview
Prayukth K V
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
SOFTTECHHUB
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
Neo4j
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
Pierluigi Pugliese
 
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
James Anderson
 
Uni Systems Copilot event_05062024_C.Vlachos.pdf
Uni Systems Copilot event_05062024_C.Vlachos.pdfUni Systems Copilot event_05062024_C.Vlachos.pdf
Uni Systems Copilot event_05062024_C.Vlachos.pdf
Uni Systems S.M.S.A.
 
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
Neo4j
 

Recently uploaded (20)

Monitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR EventsMonitoring Java Application Security with JDK Tools and JFR Events
Monitoring Java Application Security with JDK Tools and JFR Events
 
GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...
 
Essentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FMEEssentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FME
 
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...Transcript: Selling digital books in 2024: Insights from industry leaders - T...
Transcript: Selling digital books in 2024: Insights from industry leaders - T...
 
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdfSAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
SAP Sapphire 2024 - ASUG301 building better apps with SAP Fiori.pdf
 
Elevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object CalisthenicsElevating Tactical DDD Patterns Through Object Calisthenics
Elevating Tactical DDD Patterns Through Object Calisthenics
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
 
Climate Impact of Software Testing at Nordic Testing Days
Climate Impact of Software Testing at Nordic Testing DaysClimate Impact of Software Testing at Nordic Testing Days
Climate Impact of Software Testing at Nordic Testing Days
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
 
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdfFIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
FIDO Alliance Osaka Seminar: Passkeys and the Road Ahead.pdf
 
State of ICS and IoT Cyber Threat Landscape Report 2024 preview
State of ICS and IoT Cyber Threat Landscape Report 2024 previewState of ICS and IoT Cyber Threat Landscape Report 2024 preview
State of ICS and IoT Cyber Threat Landscape Report 2024 preview
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
 
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdfFIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
 
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...
 
Uni Systems Copilot event_05062024_C.Vlachos.pdf
Uni Systems Copilot event_05062024_C.Vlachos.pdfUni Systems Copilot event_05062024_C.Vlachos.pdf
Uni Systems Copilot event_05062024_C.Vlachos.pdf
 
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
GraphSummit Singapore | Graphing Success: Revolutionising Organisational Stru...
 

4. hemostasis; hemodynamic disorders

  • 1. Hemodynamic Disorders Hemodynamic Disorders  Edema  Edema  Hyperemia and Congestion  Hyperemia and Congestion  Hemorrhage  Hemorrhage  Hemostasis and Thrombosis  Hemostasis and Thrombosis  Embolism  Embolism  Infarction  Infarction  Shock  Shock 1 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 2. Feature Hemostasis Thrombosis What is it? Blood clot Blood clot Where is it? Site of vascular injury In an uninjured vessel Why is it? Trauma (common) Atherosclerosis What happens later? Stops blood loss Produce (deserved effect) complications (Emboli) 2 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 3. Hemostasis Hemostasis  Events following vascular injury  Events following vascular injury  1. transient vasoconstriction ( by neurogenic  1. transient vasoconstriction ( by neurogenic mechanisms, Endothelin – vasoconstrictor of mechanisms, Endothelin – vasoconstrictor of Endothelial cells), reduce blood loss Endothelial cells), reduce blood loss  2. Primary Hemostasis  formation of Primary  2. Primary Hemostasis  formation of Primary haemostatic plug (( by platelet adhesion, activation haemostatic plug by platelet adhesion, activation & Aggregation), & Aggregation),  3. Secondary Hemostasis  Platelets + Fibrin  3. Secondary Hemostasis  Platelets + Fibrin (( from coagulation pathways- either intrinsic or from coagulation pathways- either intrinsic or extrinsic), forms secondary haemostatic plug extrinsic), forms secondary haemostatic plug 3 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 4. Hemostasis Hemostasis  Role of Endothelium  Role of Endothelium  1. Produce Pro-thrombotic (( Plasminogen  1. Produce Pro-thrombotic Plasminogen activator inhibitors – PAI, Tissue factor, vWF) activator inhibitors – PAI, Tissue factor, vWF) and Anti-thrombotic factors (( Vasodilators – and Anti-thrombotic factors Vasodilators – PGI2, NO; tPA, Heparin like molecules & PGI2, NO; tPA, Heparin like molecules & Thombomodulin) Thombomodulin)  2. Balance of these factors determine the end result  2. Balance of these factors determine the end result (( clot or dissolution of clot) clot or dissolution of clot) 4 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 5. PAI 5 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 6. Coagulation pathway Coagulation pathway  Role of Platelets  Role of Platelets  Granules  α granules( contain clotting factors &  Granules  α granules( contain clotting factors & Growth factors), Dense or δ granules (( ADP, Ca++++, Growth factors), Dense or δ granules ADP, Ca , Neuropeptides, Epinephrine) Neuropeptides, Epinephrine)  Response to injury  bind to sub-endothelial  Response to injury  bind to sub-endothelial ECM (( vWF + Gp -Ib) Adhesion ECM vWF + Gp -Ib) Adhesion  Expose Phospholipid complexes (helps in intrinsic  Expose Phospholipid complexes (helps in intrinsic clotting pathway) & release ADP& Ca++++ clotting pathway) & release ADP& Ca  Aggregate with other platelets (( with fibrin by Gp  Aggregate with other platelets with fibrin by Gp IIb-IIIa on platelet surfaces IIb-IIIa on platelet surfaces 6 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 8. Aspirin in patients at risk for coronary thrombosis8 It irreversibly acetylates and inactivates cyclooxygenase-1  due to its ability to block TxA2 synthesis EQ Dr. Krishna Tadepalli, MD, www.mletips.com
  • 9. 9 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 10. Coagulation pathway Coagulation pathway 10 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 11. Coagulation pathway Coagulation pathway  Most important step in this pathway  Most important step in this pathway (either intrinsic or extrinsic)  formation of (either intrinsic or extrinsic)  formation of Thrombin Thrombin  Thrombin produces it effects  through  Thrombin produces it effects  through PARS( Protease activated receptors – 7 GPCR PARS( Protease activated receptors – 7 GPCR family) family)  Major effects of Thrombin  Major effects of Thrombin  Fibrin formation from Fibrinogen  Fibrin formation from Fibrinogen  On Platelets TxA2  On Platelets TxA2  On Endothelial cells NO, tPA, PGI2  On Endothelial cells NO, tPA, PGI2  act also on Lymphocytes, Neutrophils, Monocytes  act also on Lymphocytes, Neutrophils, Monocytes 11 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 12. Coagulation pathway Coagulation pathway  Thrombin  Thrombin 12 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 13. Anti -- Coagulants Anti Coagulants Natural ones Natural ones  1. Antithrombins( AT-III)  inactivate Thrombin;  1. Antithrombins( AT-III)  inactivate Thrombin; Factors IX to XII; bind to heparin like molecule on Factors IX to XII; bind to heparin like molecule on endothelium endothelium  2. Proteins – C & S  produced by liver; need Vit. K for  2. Proteins – C & S  produced by liver; need Vit. K for activation; inactivate Factors V, VIII activation; inactivate Factors V, VIII  Tissue Factor Pathway Inhibitors (TFPI)  inhibit  Tissue Factor Pathway Inhibitors (TFPI)  inhibit factors VII, X factors VII, X Clinical significance Clinical significance Heparin act through AT-III; Monitor PTT (Intrinsic pathway), Antidote is Heparin act through AT-III; Monitor PTT (Intrinsic pathway), Antidote is Protamine, can produce HIT (heparin induced thrombocytopenia); can be Protamine, can produce HIT (heparin induced thrombocytopenia); can be given in pregnancy (as it can’t cross placenta); need frequent injections given in pregnancy (as it can’t cross placenta); need frequent injections Warfarin  act through inhibition of Vit K mediated carboxylation of Warfarin  act through inhibition of Vit K mediated carboxylation of clotting factors (II,VII, IX, X); Extrinsic pathway Monitor PT; Antidote is 13 clotting factors (II,VII, IX, X); Extrinsic pathway Monitor PT; Antidote is Vit.K contraindicated in pregnancy (teratogenic) Vit.K1 1;;contraindicated in pregnancy (teratogenic) Dr. Krishna Tadepalli, MD, www.mletips.com
  • 14. Fibrinolytic pathway Fibrinolytic pathway  Most important step in this pathway  Most important step in this pathway  formation of Plasmin from Plasminogen  formation of Plasmin from Plasminogen  Tissue Plasminogen activator (tPA) is important in this  Tissue Plasminogen activator (tPA) is important in this conversion conversion  Plasmin  breaks down excess Fibrin  Fibrin split  Plasmin  breaks down excess Fibrin  Fibrin split products or Fibrin degradation products (FSP or FDP) products or Fibrin degradation products (FSP or FDP)  Most important component of FDP  D-dimer  Most important component of FDP  D-dimer Clinical significance Clinical significance D-dimer positivity (≥200 ng) patient had clot and it is lysed by D-dimer positivity (≥200 ng) patient had clot and it is lysed by Plasmin Plasmin Conditions where D-dimer is positive  DIC, DVT, PE Conditions where D-dimer is positive  DIC, DVT, PE 14 Dr. Krishna Tadepalli, MD, www.mletips.com
  • 15. Fibrinolytic pathway Fibrinolytic pathway 15 Dr. Krishna Tadepalli, MD, www.mletips.com